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INTRODUCTION:
von Hippel-Lindau disease (VHL) is a tumor predisposition syndrome characterized by the development of CNS hemangioblastomas (VHL-HB) and renal cell carcinomas (RCC) due to hypoxia inducible factor activation. Due to a lack of effective medical therapies for VHL, HBs/RCCs may lead to significant morbidity and mortality, ultimately necessitating numerous neurologic and renal surgeries. Propranolol is an FDA approved beta-1/2 antagonist discovered to harbor anti-tumor effects for infantile hemangiomas (IH), and possibly VHL-HBs. We investigated whether propranolol has anti-tumor activity against VHL-related HBs/RCCs. METHODS: Patient-derived VHL-HBs or 786-0-VHL-/-RCC cells were treated with clinically relevant concentrations of propranolol in-vitro and assessed with viability assays, flow cytometry, QT-PCR and western blots. In-vivo confirmation of propranolol anti-tumor activity was confirmed in athymic nude mice bearing 786-0 xenograft tumors. Lastly, patients enrolled in a VHL natural history study (NCT00005902) who were also on propranolol were identified. Propranolol activity against VHL-HBs was assessed retrospectively with volumetric HB growth kinetic analysis. RESULTS: Propranolol decreased HB and RCC viability in-vitro with an IC50 of 100µM and 200µM, respectively. Similar to prior reports in IH, propranolol induced apoptosis and led to increased VEGF-A mRNA expression in patient-derived VHL-HBs and 786-0 cells. Intracellular VEGF protein levels were not affected by propranolol. Tumor bearing nude mice exposed to propranolol had slower tumor progression compared to controls (33% volume reduction at 7 days, p < 0.005). Four patients harboring 76 CNS-HBs started propranolol therapy during a longitudinal VHL-HB study. HBs in these patients tended to grow slower (m=0.19 versus 0.13, p=0.4) during propranolol treatment. CON-CLUSION: Propranolol decreases VHL-HB/RCC viability in-vitro likely by apoptosis and modulation of VEGF expression. Propranolol abrogates 786-0 xenograft tumor progression in-vivo and retrospective clinical data suggests that propranolol curtails HB growth. These results suggest propranolol may play a role in treatment of VHL-related tumors. Malignant peripheral nerve sheath tumor is a soft tissue sarcoma that poses tremendous challenges for effective therapy. Several therapeutic approaches using drugs such as doxorubicin and rapamycin have been tried in the past with minimum success. Therapeutic resistant property mediated by MDR proteins, in combination with DNA damage repair was proposed as a major cause leading to therapeutic inefficacy of chemotherapeutics in MPNST tumors. To overcome this issue, we encapsulated doxorubicin in lipid nanovesicles and targeted to IL13Rα2, a receptor that is selectively overexpressed in several malignant peripheral nerve sheath tumor cell lines. In the present investigation, a MPNST mouse model was developed using STS26T-Luc cell line stably transfected with luciferase reporter gene. These cells were implanted into the sciatic nerve that could be imaged by Intravital Imaging Spectroscopy (IVIS). After confirming the tumor formation, the mice were injected with 7 mg/kg body weight of (a) IL13 linked liposomal doxorubicin (IL3LIPDXR) (b) unconjugated liposomal doxorubicin (LIPDXR) and (c) control mice injected with equal volume of saline. The mice were treated weekly once for 7 weeks. The mice which received IL13LIPDXR and LIPDXR showed significant reduction in tumor volume compared to the control group. Among the targeted and non-targeted liposomes, IL13LIPDXR showed rapid tumor regression. However, beyond 4 weeks, the drug was ineffective in shrinking or maintaining the tumor volume. This concludes that although the targeted delivery of doxorubicin, seems to be effective initially however in the later course of treatment they are ineffective in controlling the tumor progression. Approaches such as combining doxorubicin with a small molecule Ras inhibitor or other agents in the liposome formulation which are currently underway may help to improve the therapeutic efficacy. Mutant IDH1 suppresses normal IDH1 activity and alters the cellular metabolic microenvironment. We have previously identified that steadystate NAD+ level is decreased in endogenous IDH1 mutant cancers. Additionally, we found that inhibitors of the NAD+ biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT) potently depleted NAD+ and selectively induced cytotoxicity in IDH1 mutant cancers. Here, we investigated strategies to further perturb NAD+ metabolism to enhance NAMPT inhibitor efficacy in IDH1 mutant cancers. One major source of intracellular NAD+ consumption is mediated by distinct enzyme complexes of poly(ADP-ribose) polymerase (PARP). We found that temozolomide (TMZ), a commonly-used alkylating chemotherapeutic agent, transiently and potently reduced NAD+ to enhance NAMPT inhibitor efficacy in IDH1 mutant cancers. Mechanistically, TMZ stimulates an acute burst of NAD+ consumption by PARP via activation of DNA damage repair, and as a result, selectively potentiated NAD+ depletion-induced cytotoxicity in IDH mutant cells. In an in vivo IDH1 mutant cancer model, combined treatment with TMZ and NAMPT inhibitor enhanced efficacy compared to each agent alone. Thus, we find chemotherapy induces metabolic stress in IDH1 mutant cancers which can be exploited for therapeutic gain. Targeting of NAD+ homeostasis via convergent metabolic pathways could improve responses to metabolic therapy.
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